Third Rock Ventures Launches Jounce Therapeutics with $47 Million Series A to Transform Cancer Treatment
Cancer start-up will get $47m
Third Rock bankrolls cancer immunotherapy upstart with $47M A round
Having lived the early-2000s as an information technology (mostly, but with some life sciences investments because of our relationship with the National Cancer Institute) corporate VC, did I learn anything?
Yes, among them, watch for signs.